Digoxin improved some measures of quality of life at 12 months and was associated with greater reductions in NYHA class and NT-proBNP. Digoxin was also associated with fewer adverse events compared with beta-blockers.
We're working with the Arrhythmia Alliance to support clinical discussion and invaluable education around cardiac arrhythmias. The Arrhythmia Alliance supports awareness, diagnosis and treatment of cardiac arrhythmias through regular Cardiac Update Meetings, the upcoming London Arrhythmia Summit and the annual Heart Rhythm Congress.
.jpg)
